David Hutton

In a study, a team of UCLA investigators detail a deep-learning model pre-trained on 2D scans that accurately predicts disease-risk factors from 3D medical-scan modalities.

Marketed as Triesence, it is a preservative-free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.

The award from the National Institutes of Health will enable a team of researchers to investigate Alzheimer and Parkinson progression through the eye.

The NIH-supported findings could pave the way for genetic testing, clinical trials, and therapy development for these diseases.

Socioeconomic factors have long been a looming issue in various health outcomes. A team of researchers from Shanghai Jiao Tong University School of Medicine and Fudan University set out to review the impact of socioeconomic status inequality on the incidence of AMD.

The announcement marks the second FDA designation for ATSN-201, which previously received Rare Pediatric Disease designation.

The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with significant growth potential, expanding ANI’s foothold in strategic therapeutic area of ophthalmology.

Researchers from NYU Langone published a study reporting on the eye's functioning, without sight but offering hope for the future.

According to the organization, the map and report provide public, professionals and decisionmakers with data on children’s vision issues at the county and state level.

According to research conducted by investigators at the Perelman School of Medicine at the University of Pennsylvania School of Medicine, patients with a rare inherited disease affecting their sight experienced quick vision improvements that sustained for the full year-long study.

Lynn Hassman, MD, PhD, has received the Philip and Elaine Ellis New Investigator in Ophthalmology Research Award, and will focus on seeking treatment options for uveitis patients.

Research by investigators at Trinity College in Dublin shows how the gene therapy conferred significant benefit in animal models, and in human cells derived from people with glaucoma.

APP13007, according to the company, is the first product developed using Formosa’s proprietary APNT nanoparticle formulation platform.

BI 771716, with technology licensed from CDR-Life, is a highly specific antibody fragment, possibly enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.

Prevent Blindness is planning a series of events and program partnerships leading up to World Sight Day on Oct. 10, 2024.

The day will be held on October 10. It is coordinated by the International Agency for the Prevention of Blindness under the “Love Your Eyes” campaign banner, and is putting children at the center of the campaign.

Australian researchers have found that clinical registries may be an untapped font of information for artificial intelligence.

Researchers at the Medical College of Georgia at Augusta University are teaming up with Polaris Dawn to gain a better understanding of how eye changes many astronauts experience during spaceflight could ultimately leave them with multiple symptoms once they return to Earth.

The product candidate is a modifier gene therapy for broad retinitis pigmentosa indication.

The Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial, with 18 subjects, who each have received a single periocular injection of AIV007

The next step for the research likely will focus on determining whether blocking GSK3 can reverse existing AMD damage, potentially leading to new treatment options.

Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals.

According to the company, the priority review voucher would be issued upon approval of OPGx-LCA5.

According to the company, the pre-clinical safety and efficacy studies of its product have yielded positive results in 3 internationally recognized labs in India, Singapore and the United States.

In English and Spanish TV and radio spots, the public is urged to protect their vision from preventable blindness and vision loss by seeking care from a retina specialist at the first sign of retinal disease.

The Australian Society of Ophthalmologists hosted its inaugural Eye Surgery Showcase, where participants learned how ophthalmologists and the medical technology industry are working together to save the sight of Australians.

The NIH-funded study finds lack of coverage, copays, restrictive policies barriers to vital eye care for adults.

Researchers noted that patients with sickle cell disease had an increased risk of developing any retinal vascular occlusion.

Tim Cherry, PhD, and Debarshi Mustafi, MD, PhD, have been awarded a $150,000 Clinical & Research Synergy Pilot Award from Seattle Children’s Research Institute to determine the genetic causes of unsolved inherited retinal diseases.

According to the company, the FDA approval strengthens its biosimilar position in the US market.